Laser-facilitated delivery of malarial sporozoites from the skin to liver
激光促进疟疾子孢子从皮肤输送至肝脏
基本信息
- 批准号:8385605
- 负责人:
- 金额:$ 21.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAntigensAntimalarialsAreaAttenuatedBiteBlood CirculationBlood VesselsBlood capillariesCessation of lifeClinicClinicalCollaborationsConnective TissueCulicidaeCutaneousDepositionDermisDiseaseDoseEmigrationsEnsureFDA approvedFaceFiberFigs - dietaryGalactosylceramidesGeneticGoldHandImmunityImmunizationImmunologyInbred MouseInfectionIntravenousLasersLeftLicensingLifeLightingLiverLymphatic vesselMalariaMalaria VaccinesMediatingMedicineModificationMovementOne-Step dentin bonding systemOrganParasitesPlasmodium falciparumPreventionRecombinant ProteinsResearchRouteSiteSkinSporozoite vaccineSporozoitesStagingTestingTimeTranslationsTransportationTravelVaccinatedVaccinationVaccinesVirulentbasecapillarycell motilityclinical applicationexperienceimmunogenicityintradermal injectionintravenous injectionirradiationlymph nodesmouse modelpreclinical studytraffickingvaccine deliveryvaccine efficacy
项目摘要
DESCRIPTION (provided by applicant): The overall objective of this proposal is to demonstrate that laser pre-illumination can enhance skin-to-liver delivery of sporozoites (SPZs), augmenting SPZ-based vaccines. An effective, licensed anti-malarial vaccine remains an urgent need for prevention against plasmodium infection. To date, the "gold standard" for malarial vaccine developers is still immunization by bites of irradiation (g), SPZ-infected mosquitoes. However, translation of this approach into the clinic faces formidable obstacles, due to impracticality of vaccinating a large number of people by bites of infectious mosquitoes and unethic of this route of immunization. For SPZ- based vaccines, irrespective of whether the SPZs are attenuated by irradiation or genetic modification, the efficacy is correlated with the number of SPZs trafficking into the liver. While intravenous (IV) injection may be most sufficient in delivering SPZs to the liver, it is not a clinically approved route of immunization. On the othe hand, intradermal (ID) vaccination, not only mimicking natural infection but also a clinically acceptable route, is much less efficient than IV because emigration of SPZs out of the skin is restricted by the densely packed network in the dermis, which may be particularly true for cryopreserved gSPZs owing to their reduced motility. We found that laser pre-illumination of the inoculation site prior to ID enhanced skin-to-liver traffic of gSPZs to a level comparable to IV injection. The illumination transiently disrupted the dense microarchitecture of the skin, permitting relatively free movement of SPZs and their entry into the capillaries and lymphatic vessels in the dermis. We hypothesize that this laser treatment can augment ID delivery of SPZ-based vaccines and when combined with a-GalCer (a-galactosylceramide), an adjuvant for SPZ-induced immunity, can further boost SPZ-induced protection against malaria. To test this hypothesis, we will verify whether laser-mediated facilitation of skin-to-liver delivery of SPZs is
SPZ dose- and/or motility-dependent by quantification of the number of SPZs in the liver 40 hr after ID injection of varying numbers of SPZs into the site of laser illumination. This dose-dependent effect will be then tested with freshly isolated or cryopreserved gSPZs or genetically attenuated SPZs. We will also validate in outbred and inbred mouse models that laser illumination followed by ID inoculation of cryopreserved gSPZs or genetically attenuated SPZs affords similar protection against virulent SPZ infections as IV vaccination and a synergistic effect between laser and a-GalCer adjuvant on the protective immunity. The preclinical study, if successful, can potentially take SPZ-based vaccines one step closer to their clinical application.
PUBLIC HEALTH RELEVANCE: Brief cutaneous illumination with a safe and noninvasive laser will be employed to facilitate skin-to-liver transportation of live attenuated malarial sporozoite vaccine. Sufficient delivery of the vaccine to the liver will greatly boost the efficacy of the vaccine.
描述(由申请人提供):本提案的总体目标是证明激光预照明可以增强孢子子(SPZs)的皮肤到肝脏传递,增强基于spz的疫苗。预防疟原虫感染仍然迫切需要一种有效的、获得许可的抗疟疾疫苗。迄今为止,疟疾疫苗开发人员的“黄金标准”仍然是通过辐射(g)感染spz的蚊子叮咬进行免疫接种。然而,将这种方法转化为临床面临着巨大的障碍,因为通过传染性蚊子叮咬为大量人群接种疫苗不现实,而且这种免疫途径不符合伦理。对于以SPZ为基础的疫苗,无论SPZ是通过辐照还是基因改造来减毒的,其效力都与转运到肝脏的SPZ数量相关。虽然静脉注射(IV)可能最充分地将spz输送到肝脏,但它不是临床批准的免疫途径。另一方面,皮内接种(ID)疫苗,不仅模仿自然感染,也是临床可接受的途径,但效率远低于静脉注射,因为spz从皮肤中迁移受到真皮中密集排列的网络的限制,这对于冷冻保存的gspz来说尤其如此,因为它们的活动性降低。我们发现接种部位的激光预照射在注射前将gspz的皮肤到肝脏的交通增强到与静脉注射相当的水平。光照瞬间破坏了皮肤致密的微结构,允许spz相对自由地运动,并进入真皮层的毛细血管和淋巴管。我们假设这种激光治疗可以增加基于spz的疫苗的ID递送,并且当与a-GalCer (a-半乳糖神经酰胺)联合使用时,可以进一步增强spz诱导的疟疾保护。为了验证这一假设,我们将验证激光介导的促进皮肤到肝脏的spz递送是否有效
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mei X Wu其他文献
Mei X Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mei X Wu', 18)}}的其他基金
A new mucosal adjuvant for augmenting influenza vaccines in elderly
一种用于增强老年人流感疫苗接种效果的新型粘膜佐剂
- 批准号:
10409833 - 财政年份:2021
- 资助金额:
$ 21.22万 - 项目类别:
A new mucosal adjuvant for augmenting influenza vaccines in elderly
一种用于增强老年人流感疫苗接种效果的新型粘膜佐剂
- 批准号:
10304406 - 财政年份:2021
- 资助金额:
$ 21.22万 - 项目类别:
Delivery of Powdered Vaccines for Improving Newborn Vaccination
提供粉状疫苗以改善新生儿疫苗接种
- 批准号:
10092941 - 财政年份:2020
- 资助金额:
$ 21.22万 - 项目类别:
Biomimetic nanoparticles to enhance the breadth of influenza vaccines
仿生纳米颗粒可增强流感疫苗的广度
- 批准号:
10455053 - 财政年份:2020
- 资助金额:
$ 21.22万 - 项目类别:
Sample-free onsite detection of cocaine using microneedles via laser-treated skin
使用微针通过激光处理的皮肤对可卡因进行无样品现场检测
- 批准号:
9044652 - 财政年份:2016
- 资助金额:
$ 21.22万 - 项目类别:
Laser-facilitated powder-allergen delivery for epicutaneous immunotherapy
用于表皮免疫治疗的激光促进粉末过敏原递送
- 批准号:
8892996 - 财政年份:2014
- 资助金额:
$ 21.22万 - 项目类别:
Laser-facilitated powder-allergen delivery for epicutaneous immunotherapy
用于表皮免疫治疗的激光促进粉末过敏原递送
- 批准号:
8770696 - 财政年份:2014
- 资助金额:
$ 21.22万 - 项目类别:
Laser-facilitated delivery of malarial sporozoites from the skin to liver
激光促进疟疾子孢子从皮肤输送至肝脏
- 批准号:
8495256 - 财政年份:2012
- 资助金额:
$ 21.22万 - 项目类别:
Boosting Flu Vaccination without Adjuvant Injection
无需注射佐剂即可加强流感疫苗接种
- 批准号:
8263742 - 财政年份:2011
- 资助金额:
$ 21.22万 - 项目类别:
IEX-1 as a potential biomarker for early detection of myelodysplastic syndromes
IEX-1 作为早期检测骨髓增生异常综合征的潜在生物标志物
- 批准号:
8311631 - 财政年份:2011
- 资助金额:
$ 21.22万 - 项目类别:
相似海外基金
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models
在临床前小鼠和非人灵长类动物模型中确定 A 组链球菌疫苗抗原最有效的佐剂
- 批准号:
10577066 - 财政年份:2023
- 资助金额:
$ 21.22万 - 项目类别:
Lymph node-targeted codelivery of albumin-binding peptide antigens and di-adjuvant for melanoma combination immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10522591 - 财政年份:2022
- 资助金额:
$ 21.22万 - 项目类别:
Lymph Node-Targeted Codelivery of Albumin-Binding Peptide Antigens and Di-Adjuvant for Melanoma Combination Immunotherapy
用于黑色素瘤联合免疫治疗的白蛋白结合肽抗原和双佐剂的淋巴结靶向共递送
- 批准号:
10884052 - 财政年份:2022
- 资助金额:
$ 21.22万 - 项目类别:
Establishment of postoperative adjuvant immunotherapy using peptide pool of tumor antigens in advanced esophageal cancer
晚期食管癌肿瘤抗原肽库术后辅助免疫治疗的建立
- 批准号:
15K10100 - 财政年份:2015
- 资助金额:
$ 21.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of cancer vaccine using adjuvant function encrypted artificial antigens
使用佐剂功能加密人工抗原开发癌症疫苗
- 批准号:
26430172 - 财政年份:2014
- 资助金额:
$ 21.22万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
- 批准号:
7849955 - 财政年份:2009
- 资助金额:
$ 21.22万 - 项目类别:
Alpha-galactosycleramide as a mucosal adjuvant for HIV antigens
α-半乳糖酰胺作为 HIV 抗原的粘膜佐剂
- 批准号:
7627172 - 财政年份:2009
- 资助金额:
$ 21.22万 - 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
- 批准号:
2068228 - 财政年份:1992
- 资助金额:
$ 21.22万 - 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
- 批准号:
3548034 - 财政年份:1992
- 资助金额:
$ 21.22万 - 项目类别:
RECOMBINANT MIF AS AN ADJUVANT FOR HIV ANTIGENS
重组 MIF 作为 HIV 抗原的佐剂
- 批准号:
3548033 - 财政年份:1992
- 资助金额:
$ 21.22万 - 项目类别: